Match tier Listed
Presence Current · Arkansas
Last published 2026
Sources OpenAlex · ORCID
Refreshed 2026-10-05
Edward T.H. Yeh profile photo

Edward T.H. Yeh

◆ ARA Academy High Impact

Chairman

Also affiliated: Scripps Research Institute (1997); Brigham and Women's Hospital (2013–2015); Grady Memorial Hospital (2006); Arthritis Foundation (1990); St. Luke's Episcopal Hospital (1998–2015); The University of Texas MD Anderson Cancer Center (2000–2023); Harvard University (1986–2015); University of Miami (1999); The University of Texas System (2003); Duke University (1994); Baylor College of Medicine (1995–2016); China Medical University (2011); University of Toronto (2004); University of Campania "Luigi Vanvitelli" (2007–2013); University of Arkansas Medical Center (2022–2025); University of Missouri Hospital (2018); University of Rochester Medicine (2013); Massachusetts General Hospital (1989–2015); Mount Sinai Medical Center (1999); Dana-Farber Cancer Institute (2013); Temple University Health System (2013); China Medical University Hospital (2011); National Taiwan University Hospital (2013); Brown Foundation (2006–2007); Ospedale Monaldi (2011); Institute of Molecular Medicine (1997); Dana-Farber Brigham Cancer Center (2013); Elsevier BV (Netherlands) (2008); Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases (1998–2007); University of Houston (2012); Taipei Medical University (2013); University of Rochester (2013); University of Missouri (2016–2022); University of Pennsylvania (2013); Temple University (2013); Texas A&M University (2004); The University of Texas Health Science Center at Houston (1993–2011)

Department Chairs, College of Medicine

85 h-index 264 pubs 28,541 cited

  • Humans
  • Animals
  • Mice
  • Cysteine Endopeptidases
  • Male
  • Ubiquitins
  • Female
  • Sumoylation
  • Endopeptidases
  • Signal Transduction
  • SUMO-1 Protein
  • Molecular Sequence Data
  • Cells, Cultured
  • Cardiovascular Diseases
  • Amino Acid Sequence

Biography and Research Information

OverviewAI-generated summary

Edward T.H. Yeh's research group at the University of Arkansas for Medical Sciences focuses on the molecular mechanisms underlying cardiovascular complications associated with cancer therapies. His work has investigated the cardiotoxicity induced by agents such as doxorubicin and anthracyclines, as well as radiation-related heart disease. Yeh has also explored the role of C-reactive protein in cardiovascular health, specifically its proinflammatory effects on human endothelial cells and the modulation of these effects by anti-atherosclerosis drugs.

His publications include studies on the molecular basis of doxorubicin-induced cardiotoxicity and the prevention of anthracycline-induced cardiotoxicity. Yeh has also contributed to the understanding of cardiovascular complications of cancer therapy and radiation-related heart disease. He holds a high-impact researcher designation and is a member of the ARA Academy.

Yeh leads a research group and has collaborated with researchers at the University of Arkansas for Medical Sciences, including Hui‐Ming Chang on 12 shared publications. His scholarship metrics include an h-index of 88, 278 total publications, and over 29,000 total citations.

Metrics

  • h-index: 85
  • Publications: 264
  • Citations: 28,541

Positions

  • Distinguished Professor 2020–present
    University of Arkansas for Medical Sciences Internal Medicine ORCID
  • Chairman publications 1992–2026
    University of Arkansas for Medical Sciences Department Chairs, College of Medicine Institutional directory
  • Chairman 2016–2020
    University of Missouri Columbia Medicine ORCID
  • Professor and Chair 2000–2016
    The University of Texas MD Anderson Cancer Center Cardiology ORCID

Selected Publications

  • PP4 modulates macrophage-neutrophil crosstalk to restrict CCL5 -driven NETosis in sepsis (2026)
  • Prevention of Heart Failure Induced by Doxorubicin with Early Administration of Dexrazoxane (PHOENIX Study): dose response and time course of dexrazoxane-induced degradation of topoisomerase 2b (2025)
    Cardio-Oncology 4 citations DOI OpenAlex
  • CYLD links the TRAF6/sNASP axis to TLR4 signaling in sepsis-induced acute lung injury (2025)
    Cellular and Molecular Life Sciences 7 citations DOI OpenAlex
  • Microglia‐Mediated Synaptic Dysfunction Contributes to Chemotherapy‐Related Cognitive Impairment (2025)
    Journal of Neurochemistry 3 citations DOI OpenAlex
  • Abstract 12348: Targeted Degradation of Topoisomerase 2b by Dexrazoxane for Prevention of Doxorubicin-Induced Cardiotoxicity: Dose and Time Course Study in Human (2023)
    1 citation DOI OpenAlex
  • Lactate: an intracellular metabolite regulates cell cycle progression (2023)
    1 citation DOI OpenAlex
  • Corticotropin-releasing hormone neurons in the central nucleus of amygdala are required for chronic stress-induced hypertension (2023)
    Cardiovascular Research 21 citations DOI OpenAlex
  • Promises and challenges of machine learning for device therapy in heart failure (2023)
    European Heart Journal 4 citations DOI OpenAlex
  • Dipeptidylpeptidase 4 promotes survival and stemness of acute myeloid leukemia stem cells (2023)
    Cell Reports 12 citations DOI OpenAlex
  • Loss of SUMO-specific protease 2 causes isolated glucocorticoid deficiency by blocking adrenal cortex zonal transdifferentiation in mice (2022)
    Nature Communications 14 citations DOI OpenAlex
  • Signaling pathways involved in NMDA ‐induced suppression of M‐channels in corticotropin‐releasing hormone neurons in central amygdala (2022)
    Journal of Neurochemistry 7 citations DOI OpenAlex
  • Dependence of Acute Myeloid Leukemia Development on Membrane Protein Dipeptidyl Peptidase 4 (2022)
  • PEP-sNASP Peptide Alleviates LPS-Induced Acute Lung Injury Through the TLR4/TRAF6 Axis (2022)
    Frontiers in Medicine 10 citations DOI OpenAlex
  • Loss of SUMO-specific protease 2 causes isolated glucocorticoid deficiency by blocking adrenal cortex zonal transdifferentiation (2022)
  • Abstract 9710: Prevention of Doxorubicin-Induced Cardiotoxicity Through Targeted Degradation of Topoisomerase 2b (2021)

View all publications on OpenAlex →

ARA Academy 2021 ARA Scholar

Dr. Yeh's research focuses on preventative treatment for anthracycline-induced cardiotoxicity. He earned his B.S. from UC Berkeley and M.D. from UC Davis, completing postdoctoral training under Nobel Laureate Baruj Benacerraf at Harvard. He founded Cardiology at MD Anderson Cancer Center and at the University of Missouri-Columbia improved the department's NIH research ranking from 98th to 76th nationally within three years.

Policy Impact

Recruited to UAMS from MD Anderson Cancer Center. Previously improved a department's NIH ranking from 98th to 76th nationally within three years.

Growth Areas

['Population Health Innovations & Clinical Research']

Grants & Funding

As listed on this researcher's institutional profile.

  • Doxorubicin-induced Cardiotoxicity: The Role of Topoisomerase 2b NIH/Nat. Heart, Lung & Blood Institute Principal Investigator
  • PATHOBIOCHEMISTRY OF ACUTE PROMYELOCYTIC LEUKEMIA NIH Principal Investigator
  • Prevention of Heart Failure induced by Doxorubicin with Early Administration of Dexrazoxane NIH/Nat. Heart, Lung & Blood Institute Co-Investigator
  • Doxorubicin-induced Cardiotoxicity: the Role of Topoisomerase 2b NIH Principal Investigator
  • De-SUMOylation and the Hypoxic Response NIH Principal Investigator
  • STUDIES OF THE SENTRIN FAMILY OF UBIQUITIN-LIKE PROTEINS NIH Principal Investigator
  • PATHOBIOLOGY OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA NIH Principal Investigator

Collaboration Network

97 Collaborators 40 Institutions 4 Countries

Top Collaborators

View profile →

Similar Researchers

Based on overlapping research topics